Bloomberg the Company & Products

Bloomberg Anywhere Login


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

March 26, 2015 3:37 PM ET


Company Overview of KaloBios Pharmaceuticals, Inc.

Company Overview

KaloBios Pharmaceuticals, Inc., a biopharmaceutical company, develops monoclonal antibody therapeutics for the treatment of cancer in the United States. The company’s product candidates include KB004, which is in a Phase II clinical trial for the treatment of myelodysplastic syndrome and myelofibrosis; and KB003 that completed Phase II clinical trial to treat chronic myelomonocytic leukemia, an orphan oncology indication. KaloBios Pharmaceuticals, Inc. was founded in 2000 and is headquartered in South San Francisco, California.

260 East Grand Avenue

South San Francisco, CA 94080

United States

Founded in 2000

32 Employees



Key Executives for KaloBios Pharmaceuticals, Inc.

Chief Scientific Officer
Age: 62
Total Annual Compensation: $287.5K
Compensation as of Fiscal Year 2013.

KaloBios Pharmaceuticals, Inc. Key Developments

Kalobios Pharmaceuticals, Inc. Reports Consolidated Earnings Results for the Year Ended December 31, 2014

KaloBios Pharmaceuticals, Inc. reported consolidated earnings results for the year ended December 31, 2014. For the year, the company reported contract revenue of $44,000 a year ago. Loss from operations was $36,718,000 compared to $40,909,000 a year ago. Net loss was $37,998,000 or $1.15 basic and diluted per share compared to $41,948,000 or $1.73 basic and diluted per share a year ago.

KaloBios Pharmaceuticals, Inc. Auditor Raises 'Going Concern' Doubt

KaloBios Pharmaceuticals, Inc. filed its 10-K on Mar 16, 2015 for the period ending Dec 31, 2014. In this report its auditor, Ernst & Young LLP, gave an unqualified opinion expressing doubt that the company can continue as a going concern.

KaloBios Pharmaceuticals Receives Non-Compliance Notice From NASDAQ

On February 20, 2015, KaloBios Pharmaceuticals, Inc. received a deficiency letter from The NASDAQ Stock Market LLC (NASDAQ) indicating that, based on the Company’s closing bid price for the last 30 consecutive business days, the Company does not comply with the minimum bid price requirement of $1.00 per share, as set forth in NASDAQ Listing Rule 5550(a)(2). The notification has no immediate effect on the listing of the Company’s common stock on The NASDAQ Global Market. In accordance with NASDAQ Listing Rule 5810(c)(3)(A), the Company has a grace period of 180 calendar days, or until August 19, 2015, to regain compliance with the minimum closing bid price requirement for continued listing. In order to regain compliance, the minimum closing bid price per share of the Company’s common stock must be at least $1.00 for a minimum of ten consecutive business days. In the event the Company does not regain compliance by August 19, 2015, the Company may be afforded an additional 180-day compliance period, provided it demonstrates that it meets all other applicable standards for initial listing on The Nasdaq Global Market (except the bid price requirement), and provides written notice of its intention to cure the minimum bid price deficiency during the second grace period, by effecting a reverse stock split, if necessary. If the Company fails to regain compliance after the second grace period, the Company’s stock will be subject to delisting by NASDAQ. The Company is considering actions that it may take in response to this notification in order to regain compliance with the continued listing requirements.

Similar Private Companies By Industry

Company Name Region
Phthisis Diagnostics, Inc. United States
SaluMedica, LLC United States
AgBiome, LLC United States
miRagen Therapeutics, Inc. United States
EMD Serono, Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
NYC2012, Inc. United States
Lawyers Committee for Civil Rights Under Law United States
Bertelsmann AG Europe
Rush University United States
Greater Houston Partnership United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KaloBios Pharmaceuticals, Inc., please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at